Insmed’s Brinsupri Launch Recasts Growth Outlook
Insmed ((INSM)) has held its Q4 earnings call. Read on for the main highlights of the call.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Insmed’s latest earnings call struck an upbeat tone as management highlighted powerful commercial momentum, led by the Brinsupri launch, and a fortified balance sheet. Executives acknowledged some early‑stage adoption and payer friction, but framed these as manageable growing pains against a backdrop of strong revenue growth, a clearer path to cash‑flow positivity, and meaningful clinical and pipeline progress.
Brinsupri launch fuels rapid growth and bold 2026 targets
Brinsupri’s first full quarter delivered $144.6 million in net revenue, with about 11,550 new U.S. patients initiating therapy in 2025, representing less than 5% penetration of the initial target cohort. Management set an ambitious floor of at least $1 billion in Brinsupri revenue for 2026 and expects total company revenue to more than double 2025 levels, with gross‑to‑net already in the guided mid‑20s to low‑30s percent range.
ARIKAYCE momentum and a major label expansion catalyst
ARIKAYCE continued to deliver solid growth, with Japan up roughly 40% year over year and now contributing more than a quarter of global ARIKAYCE revenues, while Europe accelerated from a smaller base. The Phase III ENCORE trial readout expected in March or April 2026 could be transformational, potentially expanding the drug’s addressable market from about 30,000 patients to more than 200,000 if successful.
Robust cash position underpins path to cash-flow positivity
Insmed closed 2025 with approximately $1.4 billion in cash, cash equivalents, and marketable securities, giving the company ample runway to execute on its strategy. Management stated they expect to reach cash‑flow positivity on current plans without raising additional capital, while retaining the option to tap financing selectively to support business development or pipeline expansion.
TPIP de-risked with orphan status and Phase III on deck
The company highlighted encouraging clinical progress for TPIP (treprostinil palmitil), noting that 2025 data significantly de‑risked the asset and the FDA granted orphan drug designation in pulmonary arterial hypertension on the basis of plausible clinical superiority. A Phase III registrational trial design has been presented, and Insmed plans to initiate a PAH Phase III study in the first half of 2026 after the FDA indicated a single well‑designed trial may support filing.
Market access foundation strong with high payer approvals
Management emphasized that Brinsupri now enjoys reimbursement access for over 90% of targeted patient lives, either through formal policy or medical exception pathways. Early payer behavior appears favorable, with very high approval rates even when documentation is required, and a trend toward attestation‑based prior authorization with only modest rebates helps support attractive product economics.
Pipeline building and selective dealmaking broaden growth options
Insmed advanced its pipeline with the acquisition of INS1148, which had a one‑time cash impact in the quarter, and the initiation of two gene therapy programs in Duchenne muscular dystrophy and ALS. Leadership reiterated that business development remains a strategic priority, focusing on first‑ or best‑in‑class assets, including further DPP1 candidates, to complement internal programs and sustain long‑term growth.
Improving margin profile as Brinsupri scales
The company reported cost of product revenues of $44.2 million in 2025, equal to 16.8% of revenues and a lower percentage than in past years, reflecting Brinsupri’s positive contribution mix. Management pointed to this shift as evidence that scaling the new franchise is already lifting gross margins and could further enhance profitability as volumes grow.
Pipeline pruning with CRS program discontinuation
Not all development news was positive, as Insmed confirmed it discontinued its CRS without nasal polyps program last quarter, marking a setback in the inflammation segment of the pipeline. The move underscores a willingness to reallocate R&D resources away from lower‑conviction opportunities and toward higher‑impact respiratory and rare disease assets.
Early depth of prescribing highlights adoption risk
Despite broad uptake across roughly 4,000 prescribers in 2025, management acknowledged that the depth of Brinsupri prescribing remains shallow, with nearly half of those physicians writing the drug for only one patient so far. This early‑stage pattern introduces near‑term variability and adoption risk as refill dynamics, word‑of‑mouth effects, and physician comfort with the product mature over time.
Payer documentation requirements weigh on near-term cash
Some health plans still require more burdensome documentation, such as CT imaging and proof of at least two exacerbations, instead of simpler attestation, creating administrative friction and potential points of disruption during plan changes or reauthorizations. Management also cautioned that only a portion of booked Brinsupri revenue had been collected in cash by year‑end 2025, which temporarily impacts near‑term cash receipts even as reported sales ramp.
Higher operating spend and one-offs temporarily elevate burn
Operating expenses climbed in the fourth quarter as Insmed invested heavily in the Brinsupri launch and pipeline progression, with R&D and SG&A both moving higher. Cash burn was further inflated by about $70 million of one‑time items including the INS1148 acquisition and a milestone payment, while ARIKAYCE’s gross‑to‑net is projected to edge up to the low‑to‑mid‑20s percent in 2026 due to industry‑wide policy changes.
Ex-U.S. launch timing remains a swing factor
Investors hoping for a quick international boost from Brinsupri were reminded that ex‑U.S. contributions in 2026 will likely be minimal given original timelines. Management is awaiting greater clarity on policy details before pushing ahead with full launches in Europe and Japan, leaving the timing of meaningful overseas revenue as a key uncertainty in the medium‑term trajectory.
Guidance underscores confidence in Brinsupri’s trajectory
Looking ahead, Insmed guided Brinsupri to at least $1 billion in revenue for 2026 and expects total company sales to more than double versus 2025, anchored by a U.S. diagnosed non‑CF bronchiectasis market of about 500,000 patients and a core 250,000‑patient exacerbation segment with additional upside in COPD and asthma. With Brinsupri gross‑to‑net guided in the mid‑20s to low‑30s percent range, ARIKAYCE growth and a potential ENCORE‑driven label expansion, plus roughly $1.4 billion in cash and a stated goal of reaching cash‑flow positivity without new capital, management’s outlook remained decidedly bullish.
Insmed’s earnings call painted the picture of a company pivoting from development story to commercial growth engine, powered by Brinsupri and an improving ARIKAYCE profile. While early adoption depth, payer paperwork, and ex‑U.S. timing introduce bumps in the road, strong initial sales, robust cash reserves, and advancing late‑stage assets give management reason to project confidence in the company’s next phase of expansion.
